John Doerr
Partner and Chairman @ Kleiner Perkins
Menlo Park, United States
John Doerr is a general partner at Kleiner Perkins Caufield & Byers. Since joining KPCB in 1980, John and his partners have backed some of the world’s most successful entrepreneurs, including Larry Page, and Eric Schmidt of Google; Jeff Bezos of Amazon.com, Scott Cook and Bill Campbell of Intuit; and Mark Pincus of Zynga. John’s passion ishelping entrepreneurs create the Next Big Thing in mobile and social networks, greentech innovation, education and economic development. Ventures sponsored by John have created more than 200,000 new jobs.John serves on boards in the areas of Internet technologies and greentech, including Amyris, Bloom Energy, Coursera, Essence Healthcare, Flipboard, FloDesign Wind Turbines, Google, iControl, mCube, Quantumscape, Renmatix, Upthere and Zynga. He also led KPCB's investment in Twitter.John’s technology career began in 1974 at Intel, just as the chipmaker was inventing the groundbreaking 8080 microprocessor. During his Intel years, he held roles in engineering, marketing, management and sales. John also learned about operating excellence from Intel co-founder Andy Grove — insight that he continues to share with entrepreneurs today.He later founded Silicon Compilers, a VLSI CAD software company, and co-founded @Home, the nationwide broadband cable Internet service.Outside of KPCB, John supports entrepreneurs focused on the environment, public education and alleviating global poverty. These include NewSchools.org, TechNet.org, the Climate Reality Project and ONE.org.John earned B.S. and M.S. degrees in electrical engineering from Rice University and an M.B.A. from Harvard Business School. He also holds several patents for computer memory devices.John is a member of the American Academy of Arts and Sciences, and a member of U.S. President Barack Obama’s Council on Jobs and Competitiveness.
- Total investments:
- 122
- Last investment:
- Lead investor:
- 28%
Last updated:
For AI agents: llms.txt
Industries John Doerr invests in
Stages John Doerr invests in
Countries John Doerr invests in
Round sizes
Round size
- Series A
- $6M–$64M
- Series B
- $15M–$210M
- Series C
- $30M–$400M
Investment Focus
Industry
- Health Care 14 (11%)
- Software 12 (10%)
- Energy 9 (7%)
- Information Technology 8 (7%)
- Renewable Energy 7 (6%)
Stage
- Series B 23 (19%)
- Series A 21 (17%)
- Series C 18 (15%)
- Funding Round 11 (9%)
- Seed 7 (6%)
Country
- United States 59 (48%)
- Canada 1 (1%)
- Sweden 1 (1%)
- Germany 1 (1%)
- Switzerland 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Antora Energy
|
Antora Energy delivers zero-carbon industrial heat and power to heavy industries that are more reliable than fossil fuels. Antora’s thermal energy storage soaks up excess solar and wind electricity and uses it to heat blocks of carbon so they glow like inside a toaster. | $550M / Series C / Jul 30, 2026 | |
Isometric
|
Isometric is a carbon removal registry and science platform. | $40M / Series A / Jun 22, 2026 | |
GridCARE
|
GridCARE provides energy security and resilience at a never-before-seen pace, making it the indispensable one-stop power solution for AI data centers. | $64M / Series A / May 14, 2026 | |
Panthalassa
|
Panthalassa is a technology company focused on developing renewable energy systems in the ocean, particularly to power computing and artificial intelligence infrastructure. The company works on harnessing wave energy to generate electricity at sea, which can then be used to run offshore data centers or converted into fuels that are transported backto land. | $140M / Series B / May 04, 2026 | |
Rhoda AI
|
Rhoda is building a new class of robot foundation model designed to bring general intelligence into the physical world. By combining internet-scale video pretraining with closed-loop video predictive control, Rhoda aims to enable robots that can adapt, generalize, and operate autonomously across real-world environments. The company works withleading industrial partners across manufacturing and logistics. | $450M / Series A / Mar 10, 2026 | |
OpenEvidence
|
OpenEvidence provides an artificial intelligence medical information platform that organizes and synthesizes peer-reviewed clinical research to help physicians access evidence-based insights for clinical decision support. Its products include an AI-powered medical search engine that quickly retrieves and cites relevant literature from majorjournals and tools like DeepConsult that generate comprehensive research syntheses for complex clinical questions. The platform also integrates features that support clinical documentation and evidence retrieval during patient encounters, aiming to streamline how healthcare professionals find and apply clinical evidence. OpenEvidence delivers responses grounded in sourced medical research and supports workflows that assist clinicians in evaluating and interpreting medical knowledge. | $250M / Series D / Jan 21, 2026 | |
Hippocratic AI
|
Hippocratic AI’s Aim is to develop the safest artificial Health General Intelligence (HGI). greatly enhance healthcare access and boost the scalability of healthcare professionals using the safest artificial Health General Intelligence (HGI), resulting in a more fair system of care for all. | $126M / Series C / Nov 03, 2025 | |
|
OpenEvidence
|
OpenEvidence provides an artificial intelligence medical information platform that organizes and synthesizes peer-reviewed clinical research to help physicians access evidence-based insights for clinical decision support. Its products include an AI-powered medical search engine that quickly retrieves and cites relevant literature from majorjournals and tools like DeepConsult that generate comprehensive research syntheses for complex clinical questions. The platform also integrates features that support clinical documentation and evidence retrieval during patient encounters, aiming to streamline how healthcare professionals find and apply clinical evidence. OpenEvidence delivers responses grounded in sourced medical research and supports workflows that assist clinicians in evaluating and interpreting medical knowledge. | $200M / Series C / Oct 20, 2025 | |
|
OpenEvidence
|
OpenEvidence provides an artificial intelligence medical information platform that organizes and synthesizes peer-reviewed clinical research to help physicians access evidence-based insights for clinical decision support. Its products include an AI-powered medical search engine that quickly retrieves and cites relevant literature from majorjournals and tools like DeepConsult that generate comprehensive research syntheses for complex clinical questions. The platform also integrates features that support clinical documentation and evidence retrieval during patient encounters, aiming to streamline how healthcare professionals find and apply clinical evidence. OpenEvidence delivers responses grounded in sourced medical research and supports workflows that assist clinicians in evaluating and interpreting medical knowledge. | $210M / Series B / Jul 15, 2025 | |
Emerald AI
|
Emerald AI creates a platform that enables AI data centers to adjust power consumption from electricity grids dynamically. This system orchestrates computing loads across data centers to bolster grid reliability. The technology aims to advance AI innovation while ensuring power affordability and electric system stability. | $34.2M / Seed / Jul 01, 2025 | |
| See all 122 investments → | |||
Co-Investors
About Kleiner Perkins
Kleiner Perkins is a venture capital firm specializing in investing in early-stage, growth, and incubation companies. The firm continues that legacy, investing in founders with bold ideas that span industries and continents, partnering with them from inception to IPO and beyond to maximize the potential of their ideas. They also focus on earlycomputer firms using their devices and programming and service companies. It also invests in the digital, life sciences, and healthcare industries.
Kleiner Perkins Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brook Byers
Co-Founder
|
|||
Charles Holloway
Vice Chairman of Board of Directors
|
|||
Ilya Fushman
Partner
|
|||
Jerry Liang
Vice President
|
|||
Kevin Compton
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does John Doerr invest in?
John Doerr invests primarily in Health Care, Software and Energy startups, most often at Series B and Series A stage. Most of the 122 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is John Doerr's check size?
John Doerr typically joins rounds of $6M–$64M at Series A, $15M–$210M at Series B and $30M–$400M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds John Doerr participates in.
When did John Doerr last invest?
The most recent investment recorded for John Doerr closed in Jul 2026. Shizune tracks 122 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
